Cytomegalovirus Infection Clinical Trial Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight's, "Cytomegalovirus (CMV) Infection Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Cytomegalovirus Infection pipeline landscape. It covers the Cytomegalovirus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cytomegalovirus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Cytomegalovirus Infection Treatment Landscape @ Cytomegalovirus Infection Pipeline Outlook [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Cytomegalovirus Infection Pipeline Report

* On March 16, 2026, ModernaTX Inc . conducted a phase 2 study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.
* On March 02, 2026, Takeda initiated a study is to learn how safe maribavir is in Chinese adults who have undergone hematopoietic stem cell or organ transplantation and have a cytomegalovirus (CMV) infection and how well they tolerate treatment with maribavir. Other aims are to see how effective maribavir is in treating CMV infection and getting rid of the symptoms, the recurrence rate of CMV infection after treatment with maribavir and if the treatment is required again. Researchers will also check for changes (mutations) occurring in the virus which may cause treatment with maribavir to no longer work well or to not work at all (resistance to maribavir).
* On March 02, 2026, GlaxoSmithKline announced a phase 1/2 study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation manner, based upon safety adjudication.
* DelveInsight's Cytomegalovirus Infection pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Cytomegalovirus Infection treatment.
* The leading Cytomegalovirus Infection Companies such as Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
* Promising Cytomegalovirus Infection Pipeline Therapies such as Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.

Discover groundbreaking developments in Cytomegalovirus Infection Therapies! @ Cytomegalovirus Infection Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Cytomegalovirus Infection Overview

Cytomegalovirus (CMV) is a common virus belonging to the herpesvirus family, often causing asymptomatic infections in healthy individuals. However, it can be severe in immunocompromised patients and lead to congenital infections, which can result in long-term complications like hearing loss and developmental disabilities. CMV is widespread, with infection rates varying globally, and it has a unique ability to evade the immune system. While typically dormant after the initial infection, CMV can reactivate, posing ongoing health risks, particularly for vulnerable populations. In addition to causing congenital conditions, CMV has been linked to the development of certain cancers, including mucoepidermoid carcinoma and potentially prostate cancer. It remains a significant challenge due to its ability to persist in the body and evade immune responses.

Cytomegalovirus Infection Emerging Drugs Profile

* mRNA-1647: ModernaTX, Inc.

mRNA-1647 comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Of the six mRNAs, five encode the subunits of the CMV pentamer complex and one mRNA encodes the Glycoprotein B (gB) protein, both of which are highly immunogenic. The pentamer complex is important for CMV entry into a variety of cells, including epithelial cells, while gB is important for entry into all susceptible cells including fibroblasts. A vaccine that produces an immune response against both pentamer and gB has the potential to prevent CMV entry into a range of target cell types and thus prevent primary and congenital infections. Unlike a protein-based vaccine, mRNA-1647 instructs the body's own cells to manufacture the antigens, resulting in functional antigens that mimic those presented to the immune system by CMV during a natural infection. Preclinical data previously published in Vaccine showed that vaccination with mRNA-1647 in animal models elicited potent and durable neutralizing antibody titers. Currently, the drug is in Phase III stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

* Cytomegalovirus vaccine (Triplex) : Helocyte

The Triplex vaccine by Helocyte is a multi-antigen vaccine designed to induce a robust and durable virus-specific T-cell response against cytomegalovirus (CMV) infections, particularly in recipients of allogeneic hematopoietic stem cell transplants (HSCT) and solid organ transplants (SOT). The vaccine utilizes the Modified Vaccinia Ankara (MVA) vector to express three immunodominant CMV proteins: UL83 (pp65), UL123 (IE1), and UL122 (IE2). By targeting these proteins, Triplex stimulates a host antiviral response, enhancing both CD4+ and CD8+ T-cell responses. This mechanism of action helps control CMV infections by promoting cellular immunity, which is crucial for managing and preventing CMV-related complications in immunocompromised patients.. Currently, the drug is in Phase II stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

* VBI-1501: VBI Vaccines Inc.

VBI-1501 by VBI Vaccines Inc. is a prophylactic cytomegalovirus (CMV) vaccine candidate developed using the company's proprietary enveloped virus-like particle (eVLP) technology. This vaccine presents a modified form of the glycoprotein B (gB) found on CMV, which plays a crucial role in viral entry into host cells. The mechanism of action (MOA) of VBI-1501 involves inducing protective CMV-neutralizing antibodies that can block infection in multiple cell types, including fibroblasts and epithelial cells. By eliciting these antibodies, VBI-1501 aims to prevent CMV infection by mimicking the natural immune response observed in individuals who have developed immunity through natural infection. Currently, the drug is in Phase I stage of its development for the treatment of Cytomegalovirus (CMV) Infection.

The Cytomegalovirus Infection Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus Infection with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus Infection Treatment.
* Cytomegalovirus Infection Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cytomegalovirus Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus Infection market

Stay informed about the Cytomegalovirus Infection pipeline trends! @ Cytomegalovirus Infection Unmet Needs [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Cytomegalovirus Infection Companies

Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.

Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Cytomegalovirus Infection Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Transform your understanding of the Cytomegalovirus Infection Pipeline! @ Cytomegalovirus Infection Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Cytomegalovirus Infection Pipeline Report

* Coverage- Global
* Cytomegalovirus Infection Companies- Hoffmann-La Roche, ModernaTX, Inc., Helocyte, VBI Vaccines Inc., SpyBiotech Limited, Vir Biotechnology, Inc., GlaxoSmithKline, and EVAXION BIOTECH A/S and others.
* Cytomegalovirus Infection Pipeline Therapies- Valganciclovir, V160, Letermovir, MCMV3068A, Maribavir, mRNA-1647, Ganciclovir, Brincidofovir, and others.
* Cytomegalovirus Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cytomegalovirus Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Infectious Diseases Research-Access the Full Cytomegalovirus Infection Pipeline Analysis Today! @ Cytomegalovirus Infection Drugs and Companies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Cytomegalovirus (CMV) Infection: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cytomegalovirus (CMV) Infection- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* mRNA-1647: ModernaTX, Inc.
* Mid Stage Products (Phase II)
* Cytomegalovirus vaccine (Triplex): Helocyte
* Early Stage Products (Phase I)
* VBI-1501: VBI Vaccines Inc.
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Cytomegalovirus (CMV) Infection Key Companies
* Cytomegalovirus (CMV) Infection Key Products
* Cytomegalovirus (CMV) Infection- Unmet Needs
* Cytomegalovirus (CMV) Infection- Market Drivers and Barriers
* Cytomegalovirus (CMV) Infection- Future Perspectives and Conclusion
* Cytomegalovirus (CMV) Infection Analyst Views
* Cytomegalovirus (CMV) Infection Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-infection-clinical-trial-pipeline-appears-robust-with-15-key-pharma-companies-actively-working-in-the-domain-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.